A Phase 3 interventional study of CD5024 and Azelaic acid 15% Gel in Papulopustular Rosacea, sponsored by Galderma R&D. Completed at 50 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing ivermectin in Rosacea — none open to participants now, none under way, none of them phase 3. Ivermectin · Rosacea.
Among the 11 studies testing ivermectin in Rosacea, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 3, and was the 1st registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 11 studies testing ivermectin in Rosacea is open now. The open studies under Rosacea, anywhere →
Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2011; this study’s year is marked. 2 started in 2011.
This study's enrollment of 688 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 486 across the 11 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2011, is one of 11 in phase 3, and was the 15th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing ivermectin in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CD5024 1% Cream
Drug: CD5024
CD5024 Vehicle Cream
Drug: Azelaic acid 15% Gel
CD5024 1% Cream, once daily
Topical Gel applied twice daily
Success Rate
Percentage of subjects who achieve "Clear" (Score 0) or "Almost Clear" (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score. Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale: Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)
Time frame: Week 12
Absolute Change in Inflammatory Lesion Count
Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).
Time frame: Baseline to Week 12
Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)
Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).
Time frame: Baseline to Week 12
| Milestone | CD5024 1% Cream | CD5024 Vehicle Cream/Azelaic Acid 15% Gel |
|---|---|---|
| Started | 459 | 229 |
| Completed | 429 | 208 |
| Not completed | 30 | 21 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Adverse event | 6 | 4 |
| Withdrew: Withdrawal by subject | 9 | 8 |
| Withdrew: Protocol violation | 4 | 0 |
| Withdrew: Lost to follow-up | 8 | 8 |
| Withdrew: Other | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Milestone | CD5024 1% Cream | CD5024 Vehicle Cream/Azelaic Acid 15% Gel |
|---|---|---|
| Started | 428 | 208 |
| Completed | 353 | 159 |
| Not completed | 75 | 49 |
| Withdrew: Pregnancy | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Withdrawal by subject | 32 | 24 |
| Withdrew: Protocol violation | 3 | 5 |
| Withdrew: Lost to follow-up | 26 | 10 |
| Withdrew: Other (noted in ecrf) | 8 | 2 |
| Milestone | CD5024 1% Cream | CD5024 Vehicle Cream/Azelaic Acid 15% Gel |
|---|---|---|
| Started | 353 | 159 |
| Completed | 353 | 159 |
| Not completed | 0 | 0 |
Percentage of subjects who achieve "Clear" (Score 0) or "Almost Clear" (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score. Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale: Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)
| Percentage of participants | CD5024 1% Cream | CD5024 Vehicle Cream |
|---|---|---|
| Success Rate | 40.1 | 18.8 |
Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).
| Lesion count change | CD5024 1% Cream | CD5024 Vehicle Cream |
|---|---|---|
| Absolute Change in Inflammatory Lesion Count | -22.2 ± 14.87 | -13.4 ± 14.48 |
Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).
| Percentage of change in lesion counts | CD5024 1% Cream | CD5024 Vehicle Cream |
|---|---|---|
| Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF) | -65.7 ± 33.18 | -43.4 ± 38.42 |
Collected over Time of signed informed consent to study end (~ 58 wks). Treatment emergent adverse events - occurred on date of 1st use of medication or after, except those reported from Day 1 lab data as blood sample was to be drawn before the time of 1st dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD5024 1% Cream - Part A | — | 7/458 (1.5%) | 33/458 (7.2%) |
| CD5024 Vehicle Cream - Part A | — | 4/230 (1.7%) | 26/230 (11.3%) |
| CD5024 1% Cream - Part B | — | 13/428 (3%) | 102/428 (23.8%) |
| Azelaic Acid 15% Gel - Part B | — | 4/208 (1.9%) | 47/208 (22.6%) |
| CD5024 1% Cream - Part C | — | 0/353 (0%) | 4/353 (1.1%) |
| CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part C | — | 1/159 (0.6%) | 3/159 (1.9%) |
| CD5024 1% Cream - Overall | — | 18/460 (3.9%) | 125/460 (27.2%) |
| CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall | — | 9/231 (3.9%) | 64/231 (27.7%) |
| Event | CD5024 1% Cream - Part A | CD5024 Vehicle Cream - Part A | CD5024 1% Cream - Part B | Azelaic Acid 15% Gel - Part B | CD5024 1% Cream - Part C | CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part C | CD5024 1% Cream - Overall | CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall |
|---|---|---|---|---|---|---|---|---|
| HypertensionVascular disorders | 0/458 | 1/230 | 0/428 | 1/208 | 0/353 | 0/159 | 0/460 | 2/231 |
| NephrolithiasisRenal and urinary disorders | 0/458 | 0/230 | 0/428 | 0/208 | 0/353 | 1/159 | 0/460 | 1/231 |
| Angina pectorisCardiac disorders | 0/458 | 0/230 | 1/428 | 1/208 | 0/353 | 0/159 | 1/460 | 1/231 |
| Aortic valve stenosisCardiac disorders | 0/458 | 0/230 | 0/428 | 1/208 | 0/353 | 0/159 | 0/460 | 1/231 |
| HeadacheNervous system disorders | 0/458 | 0/230 | 0/428 | 1/208 | 0/353 | 0/159 | 0/460 | 1/231 |
| Transient ischaemic attackNervous system disorders | 0/458 | 0/230 | 0/428 | 1/208 | 0/353 | 0/159 | 0/460 | 1/231 |
| DiverticulitisInfections and infestations | 0/458 | 0/230 | 0/428 | 1/208 | 0/353 | 0/159 | 0/460 | 1/231 |
| Incisional herniaInjury, poisoning and procedural complications | 0/458 | 0/230 | 0/428 | 1/208 | 0/353 | 0/159 | 0/460 | 1/231 |
| Chest discomfortGeneral disorders | 0/458 | 0/230 | 0/428 | 1/208 | 0/353 | 0/159 | 0/460 | 1/231 |
| DepressionPsychiatric disorders | 2/458 | 0/230 | 0/428 | 0/208 | 0/353 | 0/159 | 2/460 | 0/231 |
| Event | CD5024 1% Cream - Part A | CD5024 Vehicle Cream - Part A | CD5024 1% Cream - Part B | Azelaic Acid 15% Gel - Part B | CD5024 1% Cream - Part C | CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part C | CD5024 1% Cream - Overall | CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 10/458 | 6/230 | 43/428 | 18/208 | 1/353 | 1/159 | 52/460 | 23/231 |
| Upper respiratory tract infectionInfections and infestations | 12/458 | 8/230 | 40/428 | 17/208 | 1/353 | 2/159 | 48/460 | 23/231 |
| SinusitisInfections and infestations | 9/458 | 6/230 | 20/428 | 7/208 | 2/353 | 0/159 | 30/460 | 13/231 |
| Skin irritationSkin and subcutaneous tissue disorders | 3/458 | 7/230 | 4/428 | 8/208 | 0/353 | 0/159 | 6/460 | 15/231 |
ITT population
| Age, Continuous(Year) | CD5024 1% Cream | CD5024 Vehicle Cream/Azelaic Acid 15% Gel | Total |
|---|---|---|---|
| Mean | 50.5 ± 12.35 | 49.5 ± 12.16 | 50.2 ± 12.29 |
| Sex: Female, Male(Participants) | CD5024 1% Cream | CD5024 Vehicle Cream/Azelaic Acid 15% Gel | Total |
|---|---|---|---|
| Female | 314 | 145 | 459 |
| Male | 145 | 84 | 229 |
| Ethnicity (NIH/OMB)(Participants) | CD5024 1% Cream | CD5024 Vehicle Cream/Azelaic Acid 15% Gel | Total |
|---|---|---|---|
| Hispanic or Latino | 56 | 31 | 87 |
| Not Hispanic or Latino | 403 | 198 | 601 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CD5024 1% Cream | CD5024 Vehicle Cream/Azelaic Acid 15% Gel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 10 | 5 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 4 | 10 |
| White | 438 | 218 | 656 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 2 | 7 |
| Skin Photo Type(Participants) | CD5024 1% Cream | CD5024 Vehicle Cream/Azelaic Acid 15% Gel | Total |
|---|---|---|---|
| I | 48 | 22 | 70 |
| II | 211 | 96 | 307 |
| III | 139 | 71 | 210 |
| IV | 50 | 31 | 81 |
| V | 11 | 7 | 18 |
| VI | 0 | 2 | 2 |
The record gives a start of Dec 2011, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 5 months after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin